Diabetes is a risk factor for the progression and prognosis of COVID-19.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. · 2020
Read Diabetes is a risk factor for the progression and prognosis of COVID-19. by Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7228407.txt.
Introduction
Guo and co-authors test whether diabetes worsens the course of COVID-19. Their study appeared in Diabetes/Metabolism Research and Reviews. They studied 174 consecutive confirmed patients. Of these, 24 had diabetes but no other major illnesses. That clean comparison isolates diabetes itself as a factor.
Patients with diabetes faced higher risk of severe pneumonia. Their blood showed more tissue injury enzymes and stronger inflammation. Clotting ran high, tied to disturbed sugar control. Lymphocyte counts and hemoglobin ran lower than in other patients. The authors conclude diabetes contributes to poorer outcomes. They argue such patients need closer monitoring from admission. The study was among the early ones to separate diabetes from general frailty.
Catalog record
| CREATOR | Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Diabetes is a risk factor for the progression and prognosis of COVID‐19 By Weina Guo, Mingyue Li, Yalan Dong, Haifeng Zhou, Zili Zhang, Chunxia Tian, Renjie Qin, Haijun Wang, Yin Shen, Keye Du, Lei Zhao, Heng Fan Published in: Diabetes/Metabolism Research and Reviews DOI: 10.1002/dmrr.3319 ABSTRACT Abstract Backgound To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID‐19). Methods A total of 174 consecutive patients confirmed with COVID‐19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well the treatment measures were collected and analysed. Results We found that COVID‐19 patients without other comorbidities but with diabetes (n = 24) were at higher risk of severe pneumonia, release of tissue injury‐related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation‐related biomarkers such as IL‐6, C‐reactive protein, serum ferritin and coagulation index, D‐dimer, were significantly higher (P < .01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID‐19. Conclusions Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID‐19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration. INTRODUCTION Since the end of 2019, a newly identified illness termed COVID‐19 has spread rapidly through China and the rest of the world. A novel beta‐coronavirus, known as the severe acute respiratory syndrome corona virus 2 (SARS‐CoV‐2), was identified as the COVID‐19 pathogen, which triggered severe pneumonia and acute, even lethal, lung failure. 1 By 2 March 2020, the virus had caused 80 303 confirmed cases and 2948 deaths in China and cases have been reported in 45 countries, including the United States, Korea, Japan and Italy. In the existing cases, some patients with SARS‐CoV‐2 pneumonia developed acute respiratory distress syndrome (ARDS), and a part of them worsened in a short period of time and died of multiple organ failure. 1 Angiotensin‐converting enzyme 2 (ACE2) is the surface receptor for SARS coronavirus (SARS‐CoV), directly interacting with the spike glycoprotein (S protein). 2 A recent study suggests that the affinity between ACE2 and the receptor‐binding domain (RBD) of SARS‐CoV‐2 is 10 to 20 times higher than that with the RBD of SARS‐CoV, indicating that ACE2 might also be the receptor for SARS‐CoV‐2. 3 ACE2 was reported to be widely expressed in various organ systems including the cardiovascular system, kidneys, lungs and brain, 4 , 5 which might provide an explanation for why some COVID‐19 patients died of multiple organ failure. Diabetes mellitus is one of the leading causes of morbidity worldwide and is anticipated to rise substantially over the next decades. 6 Several investigations have demonstrated a higher susceptibility to some infectious diseases in diabetic people, like Staphylococcus aureus and Mycobacterium tuberculosis, 7 , 8 , 9 probably owing to the dysregulated immune system. 10 It has reported that plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. 11 A retrospective study in Wuhan, China revealed that of the 41 COVID‐19 patients, 32% of them had underlying diseases, and among which 20% was diabetes. 12 Therefore, these diabetic patients might be at increased risk of COVID‐19 and have a poorer prognosis. To figure out whether diabetes is a risk factor to influence the progression and prognosis of COVID‐19, 174 COVID‐19 patients who were admitted to Wuhan Union Hospital from 10 February 2020 to 29 February 2020 were included in this study according to the inclusion criteria. Their basic information, laboratory examinations, chest computed tomography (CT) scans as well the treatment measures were collected and analysed. We found that, as a common underlying disease in COVID‐19 patients, diabetes is associated with worse prognosis. MATERIALS AND METHODS This was a retrospective study of 174 patients with SARS‐Cov‐2 infection who were admitted to Wuhan Union hospital from 10 February 2020 to 29 February 2020. The enrolled patients in this study are all diagnosed with COVID‐19 according to WHO interim guidance. Wuhan Union Hospital is a designated hospital for treating COVID‐19. In the first part, we divided all patients into two groups based on whether they had diabetes. In the second part, we excluded patients with comorbidities other than diabetes to avoid the impact of other comorbidities, and then the patients with diabetes and patients without diabetes were separated into two groups. This case series was approved by the Institutional Ethics Board of Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. Written informed consent was waived by the Ethics Commission of the designated hospital for the emerging infectious diseases. We extracted demographic data, medical history, exposure history, symptoms and signs, laboratory findings, chest CT scans, and the treatment measures from electronic medical records. The date of disease onset was defined as the day when the first symptom showed up. Clinical outcomes were followed up to 3 March 2020. All data were analysed by the research team and double checked by two physicians (Y.S. and L.Z.). Laboratory validation of SARS‐CoV‐2 was performed at Wuhan Union Hospital. Throat‐swab specimens that obtained from the upper respiratory tract of patients at admission were stored in viral‐transport medium. Total RNA was extracted within 2 hours using the respiratory sample RNA isolation kit (Zhongzhi, Wuhan, China). SARS‐CoV‐2 was examined by RT‐PCR as described previously. 12 All COVID‐19 patients met the following criteria: (a) Epidemiology history, (b) Fever or other respiratory symptoms, (c) Typical CT image abnormities of viral pneumonia, and (d) Positive result of RT‐PCR for SARS‐CoV‐2 RNA. Patients were divided into the diabetes and non‐diabetes group according to their medical history. Furthermore, CT imaging scores were used to quantify the pathological changes of COVID‐19 patients. The values were obtained by two physicians, who were blinded to the patients' clinical data, using an introduced scoring system described as below.No.PerformanceScore(1)Unbilateral patchy shadows or ground‐glass opacity5(2)Bilateral patchy shadows or ground‐glass opacity7(3)Diffuse changes for (1) or (2)2(4)Unbilateral solid shadow, strip shadow2(5)Bilateral solid shadow, strip shadow4(6)Unbilateral pleural effusion2(7)Bilateral pleural effusion4(8)Increased or enlarge mediastinal lymph nodes1 Categorical variables were expressed as frequency rates and percentages (%), and continuous variables were expressed as mean (SD) if they are normally distributed or median (IQR) if not. Categorical variables between groups were compared using the χ2 test or Fisher exact test, and continuous variables were analysed using Student's t test or Mann‐Whitney U test as appropriate. All statistical analyses were performed using the SPSS 13.0 software. a P‐value <.05 was considered statistically significant. RESULTS Of 174 hospitalized patients with COVID‐19, the median age was 59 years (interquartile range, 49‐67) and 76 (43.7%) were men. For the all patients the most common symptoms were fever (78.2%), chill (68.4%), cough (32.2%), fatigue (27%), chest tightness (25.9%), shortness of breath (24.1%) and myalgia (20.7%), whereas nausea (9.8%), headache (6.9%), pharyngalgia (5.2%) and chest pain (8.6%) were relatively rare. The most common of underlying comorbidities were chronic diseases, such as hypertension (24.7%) and diabetes (21.2%). Compared with patients without diabetes, patients with diabetes had more cardiovascular disease (32.4% vs 14.6%) and